当前位置: X-MOL 学术Diabetes Res. Clin. Pract. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Diabetes Research and Clinical Practice ( IF 6.1 ) Pub Date : 2019-12-20 , DOI: 10.1016/j.diabres.2019.107981
Ilaria Dicembrini 1 , Chiara Montereggi 1 , Besmir Nreu 1 , Edoardo Mannucci 1 , Matteo Monami 1
Affiliation  

AIM Observational studies and metanalyses of randomized trials on Dipeptidyl Peptidase-4 inhibitors (DPP4i) reported discordant results on the risk of pancreatitis and pancreatic cancer with this class of drugs. Aim of the present meta-analysis is the assessment of the effect of DPP4i treatment on the incidence of pancreatitis and pancreatic cancer, collecting all available evidence from randomized controlled trials. Methods Data Sources: an extensive Medline, Embase and Cochrane Database search for sitagliptin or vildagliptin or omarigliptin or saxagliptin or alogliptin or trelagliptin or anagliptin or linagliptin or gemigliptin or evogliptin or teneligliptin was performed up to up to September 30th, 2019. All trials performed on type 2 diabetes, with duration ≥24 weeks, and comparing of DPP4i with placebo or active drugs were collected. The study has been registered on PROSPERO (#153344). Mantel-Haenszel odds ratio (MH-OR) with 95% Confidence Interval (95% CI) was calculated for all outcomes defined above. Results A total of 165 eligible trials were identified. DPP-4 inhibitors were not associated with an increased risk of pancreatitis (MH-OR 1.13 [0.86, 1.47]) or pancreatic cancer (MH-OR 0.86 [0.60, 1.24]) with no significant differences across individual molecules of the class. CONCLUSIONS available data do not support the hypothesis of an association of DPP4i treatment with pancreatitis. Present data do not suggest any association of DPP4i with pancreatic cancer, although they are insufficient to draw definitive conclusions.

中文翻译:

用二肽基肽酶-4抑制剂治疗的患者的胰腺炎和胰腺癌:随机对照试验的广泛和更新的荟萃分析。

目的对Depteptidyl Peptidase-4抑制剂(DPP4i)进行的观察性研究和随机试验的荟萃分析报告了此类药物对胰腺炎和胰腺癌风险的不一致结果。本荟萃分析的目的是评估DPP4i治疗对胰腺炎和胰腺癌的发生率的影响,并从随机对照试验中收集所有可用证据。方法数据来源:截至2019年9月30日进行了广泛的Medline,Embase和Cochrane数据库搜索西他列汀或维达列汀或奥格列汀或沙格列汀或阿格列汀或Trelagliptin或Anagliptin或linagliptin或Geigliptin或evogliptin或Teneligliptin。所有试验均进行。所有试验。收集了持续时间≥24周的2型糖尿病,并将DPP4i与安慰剂或活性药物进行了比较。该研究已在PROSPERO(#153344)上注册。对于以上定义的所有结果,计算了95%置信区间(95%CI)的Mantel-Haenszel比值比(MH-OR)。结果总共鉴定了165个合格试验。DPP-4抑制剂与胰腺炎(MH-OR 1.13 [0.86,1.47])或胰腺癌(MH-OR 0.86 [0.60,1.24])的患病风险增加没有相关性,各个类别的分子之间无显着差异。结论现有数据不支持DPP4i治疗与胰腺炎相关的假设。尽管目前的数据不足以得出明确的结论,但目前的数据并未提示DPP4i与胰腺癌有任何关联。对于以上定义的所有结果,计算了95%置信区间(95%CI)的Mantel-Haenszel比值比(MH-OR)。结果总共鉴定了165个合格试验。DPP-4抑制剂与胰腺炎(MH-OR 1.13 [0.86,1.47])或胰腺癌(MH-OR 0.86 [0.60,1.24])的患病风险增加没有相关性,各个类别的分子之间无显着差异。结论现有数据不支持DPP4i治疗与胰腺炎相关的假设。尽管目前的数据不足以得出明确的结论,但目前的数据并未提示DPP4i与胰腺癌有任何关联。对于以上定义的所有结果,计算了95%置信区间(95%CI)的Mantel-Haenszel比值比(MH-OR)。结果总共鉴定了165个合格试验。DPP-4抑制剂与胰腺炎(MH-OR 1.13 [0.86,1.47])或胰腺癌(MH-OR 0.86 [0.60,1.24])的患病风险增加没有相关性,各个类别的分子之间无显着差异。结论现有数据不支持DPP4i治疗与胰腺炎相关的假设。尽管目前的数据不足以得出明确的结论,但目前的数据并未提示DPP4i与胰腺癌有任何关联。[1.24]),该类别的各个分子之间没有显着差异。结论现有数据不支持DPP4i治疗与胰腺炎相关的假设。尽管目前的数据不足以得出明确的结论,但目前的数据并未提示DPP4i与胰腺癌有任何关联。[1.24]),该类别的各个分子之间没有显着差异。结论现有数据不支持DPP4i治疗与胰腺炎相关的假设。尽管目前的数据不足以得出明确的结论,但目前的数据并未提示DPP4i与胰腺癌有任何关联。
更新日期:2019-12-20
down
wechat
bug